Covid-19 Research

Special Issue

Metabolic Reset: Diabetes, Endocrine Signals & Next Therapies

A JBRES Special Issue dedicated to rigorous, outcome-oriented advances in diabetes and endocrinology—linking endocrine signaling insights, metabolic biomarkers, next-generation therapies, and clinical translation to reset metabolic health and improve long-term outcomes.

Home › Special Issues › Metabolic Reset
Submit Manuscript All Special Issues
JBRES Special Issue • Endocrinology & Metabolic Disorders
Special Issue Title

Metabolic Reset: Diabetes, Endocrine Signals & Next Therapies

This Special Issue of the Journal of Biomedical Research & Environmental Sciences (JBRES) invites high-quality submissions that strengthen the evidence base for diabetes and metabolic disorders. We welcome work that elucidates endocrine signaling pathways, identifies novel biomarkers, and demonstrates next-generation therapies & real-world effectiveness across type 1/2 diabetes, prediabetes, and related endocrine conditions.

Endocrine Signals & Biomarkers
Incretin pathways, beta-cell function markers, multi-omics signatures, inflammatory cytokines, precision risk profiling, predictive biomarkers.
Next Therapies & Translation
GLP-1/GIP/dual/triple agonists, oral incretins, SGLT2i combos, beta-cell preservation, precision approaches, implementation in diverse populations.
Submit to This Special Issue Submission Guidelines Peer Review Policy

About this Special Issue

Metabolic disorders research is strongest when it connects endocrine signaling insights with innovative therapies and meaningful outcomes. This Special Issue focuses on diabetes and endocrine reset—from signaling pathways and biomarker discovery to next-generation treatments, prevention strategies, and policy-relevant translation. We especially welcome submissions that report transparent methods, practical endpoints, and insights that can improve glycemic control, equity, and long-term metabolic well-being.

Preference is given to studies with clear outcomes (HbA1c, weight loss, CV/renal events, beta-cell function), robust analysis, and a concise “What this changes in practice” statement.

Topics of interest

Submissions may address (but are not limited to):

Type 1 & Type 2 Diabetes Management Incretin Signaling & GLP-1/GIP Pathways Dual/Triple Agonists (Tirzepatide, Retatrutide) Oral GLP-1 & Next-Gen Therapies Beta-Cell Preservation & Regeneration Metabolic Biomarkers & Precision Profiling SGLT2 Inhibitors & Combination Strategies Prediabetes & Prevention Approaches Endocrine Signals in Obesity & Metabolism Real-World Evidence & Implementation Personalized Medicine in Diabetes Complications (CV, Renal, Neuropathy)

Article types accepted

  • Original Research Articles
  • Clinical Trials & Intervention Studies
  • Observational & Population Studies
  • Review Articles
  • Systematic Reviews & Meta-Analyses
  • Mini-Reviews
  • Short Communications
  • Case Studies (where appropriate)
Tip: Include (1) primary/secondary outcomes, (2) a brief methods transparency note (preregistration/data availability if applicable), and (3) a “Clinical/Community Relevance” paragraph.

Why submit to this Special Issue?

  • Metabolic-forward visibility: your work is presented alongside leading diabetes, endocrine, and next-therapy research.
  • Efficient editorial pathway: JBRES targets rapid peer review (7–14 days where applicable).
  • Permanent DOI: accepted articles receive DOI for strong citation continuity.
  • Open access reach: broad discoverability for clinicians, researchers, and endocrinology teams.
  • Author support: clear guidance through review, proofing, and publication.
Ready to submit?
Submit online, or share an abstract for an editorial scope check (methods + outcomes summary preferred).
Submit Manuscript Email Abstract
Submission Portal Submission Instructions Aims & Scope Archive
Alternative submission emails: support@jelsciences.com | editor.review@scireslit.us
License (upon publication): Creative Commons CC BY 4.0
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership